Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockGet instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Tarsons Products Limited is an Indian labware manufacturer designing, developing, manufacturing and marketing consumables, reusables and benchtop instruments used by research organisations, academia, pharma, CROs, diagnostics and hospitals; the company operates multiple automated clean-room plants, sells 2,000+ SKUs across 350 product segments, and serves domestic and export customers through a pan-India distributor network and 45+ overseas partners.
Tarsons reported steady top-line growth in Q3FY26 with consolidated revenue growing 12.8% year-on-year and consolidated EBITDA increasing 6.3% to INR 31.5 crore; however, reported PAT is depressed due to accelerated depreciation and higher finance costs from partial capitalization of new facilities at Panchla and Amta, while adjusted cash PAT grew strongly, indicating cash-generative operations.
The business is undergoing a strategic transformation: Tarsons is commissioning large new facilities (Panchla and Amta) in Q4 FY26 to enter cell culture and bioprocess product categories and to establish an in-house sterilization and fulfilment centre; management expects the new capacities to expand addressable market and support export-led growth, though meaningful revenue from these assets is expected to materialize over the next 2-3 years.
Tarsons has increased its overseas revenue mix — consolidated overseas share crossed 50% in the latest quarter — and owns European distribution through the Nerbe acquisition, positioning the company to benefit from tariff improvements from trade agreements and currency moves; the firm pursues both branded and ODM routes to capture global market share while leveraging Make-in-India cost advantages.
The company combines a legacy brand (40+ years), high automation (robotic ISO clean rooms), vertical integration and a diversified product portfolio, but faces industry-wide pricing pressure from capacity additions post-COVID and inventory/work-capital intensity given large SKU counts, making execution on ramp-up, product qualification and working-capital optimisation critical for near-term margin recovery.
Healthcare Equipment & Supplies
Medical Equipment & Supplies
1,272 Cr
Moderate Risk
88.9
41.7
0.7
2.0
405.30
164.15
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Discovery themes featuring this stock
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Tarsons Products Ltd (TARSONS) is currently trading at 278.65 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Tarsons Products Limited is an Indian labware manufacturer designing, developing, manufacturing and marketing consumables, reusables and benchtop instruments used by research organisations, academia, pharma, CROs, diagnostics and hospitals; the company operates multiple automated clean-room plants, sells 2,000+ SKUs across 350 product segments, and serves domestic and export customers through a pan-India distributor network and 45+ overseas partners. Tarsons reported steady top-line growth in Q3FY26 with consolidated revenue growing 12.8% year-on-year and consolidated EBITDA increasing 6.3% to INR 31.5 crore; however, reported PAT is depressed due to accelerated depreciation and higher finance costs from partial capitalization of new facilities at Panchla and Amta, while adjusted cash PAT grew strongly, indicating cash-generative operations. The business is undergoing a strategic transformation: Tarsons is commissioning large new facilities (Panchla and Amta) in Q4 FY26 to enter cell culture and bioprocess product categories and to establish an in-house sterilization and fulfilment centre; management expects the new capacities to expand addressable market and support export-led growth, though meaningful revenue from these assets is expected to materialize over the next 2-3 years. Tarsons has increased its overseas revenue mix — consolidated overseas share crossed 50% in the latest quarter — and owns European distribution through the Nerbe acquisition, positioning the company to benefit from tariff improvements from trade agreements and currency moves; the firm pursues both branded and ODM routes to capture global market share while leveraging Make-in-India cost advantages. The company combines a legacy brand (40+ years), high automation (robotic ISO clean rooms), vertical integration and a diversified product portfolio, but faces industry-wide pricing pressure from capacity additions post-COVID and inventory/work-capital intensity given large SKU counts, making execution on ramp-up, product qualification and working-capital optimisation critical for near-term margin recovery.
Over the past 52 weeks, Tarsons Products Ltd has traded between a low of ₹164.15 and a high of ₹405.30. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Tarsons Products Ltd has a market capitalization of approximately 1,272.43. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Tarsons Products Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 88.86 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,272.43 Cr, Tarsons Products Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Tarsons Products Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Tarsons Products Ltd is 88.86. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Bearish
7
Neutral
2
Bullish
5
Bearish
7
Neutral
2
Bullish
37
Bearish
0
Neutral
0
Bullish
32
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
278.65 | 1,272 Cr | 88.86 | 2.00 | 0.00 | 2.26 | 4.09 | 1.21 | ||
224.40 | 1,251 Cr | 43.17 | 5.14 | 0.00 | 13.74 | 14.03 | 8.99 | ||
509.65 | 1,171 Cr | 25.98 | 2.71 | 0.00 | 21.29 | 14.24 | 0.00 | ||
479.20 | 896 Cr | 30.68 | 4.41 | 0.00 | 14.31 | 18.03 | 8.19 | ||
158.50 | 704 Cr | 18.36 | 1.68 | 0.38 | 9.14 | 10.71 | 5.87 | ||
370.95 | 649 Cr | 63.39 | 3.73 | 0.00 | 5.88 | 7.65 | 5.02 | ||
366.45 | 548 Cr | 30.13 | 3.28 | 0.00 | 13.22 | 14.71 | 6.63 | ||
| Median: 7 Co. | — | 366.45 | 896 Cr | 30.68 | 3.28 | 0.00 | 13.22 | 14.03 | 5.87 |
